Control group (n = 214) | Protein-loading group (n = 110) | p-value (unadjusted) | p-value (adjusted)a | |
---|---|---|---|---|
Serum creatinine, mg/dLb | ||||
Hospital admission | 0.85 (0.72 – 0.96) | 0.84 (0.73 – 0.96) | 0.998 | 0.930 |
Preoperative | 0.84 (0.72 − 0.95) | 0.83 (0.72 − 0.96) | 0.956 | 0.883 |
Postoperative day 1 | 0.77 (0.65 − 0.89) | 0.79 (0.70 − 0.88) | 0.181 | 0.148 |
Postoperative day 2 | 0.84 (0.70 − 0.96) | 0.82 (0.70 − 0.96) | 0.308 | 0.251 |
Hospital discharge | 0.8 (0.67 − 0.92) | 0.78 (0.69 − 0.93) | 0.990 | 0.924 |
3-month follow-up | 0.90 (0.76 − 1.00) | 0.83 (0.72 − 0.95) | 0.088 | 0.048 |
1-year follow-up | 0.95 (0.81 – 1.09) | 0.87 (0.76 – 0.93) | < 0.001 | < 0.001 |
eGFR, mL/min/1.73 m2 c | ||||
Hospital admission | 90 (80 − 98) | 91 (82 − 100) | 0.886 | 0.823 |
Preoperative | 91 (80 − 98) | 92 (82 − 100) | 0.886 | 0.823 |
Hospital discharge | 94 (85 − 102) | 93 (85 − 102) | 0.774 | 0.767 |
3-month follow-up | 87 (77 − 95) | 91 (82 − 100) | 0.033 | 0.028 |
1-year follow-up | 81 (70 − 88) | 88 (78 − 96) | < 0.001 | < 0.001 |
Albuminuria, mg/g creatinine | ||||
Hospital admission | 7.0 (3.6 − 24.1) | 6.5 (3.3 − 21.0) | 0.273 | 0.265 |
3-month follow-up | 14.1 (4.3 − 62.1) | 7.9 (1.6 − 43.9) | 0.076 | 0.065 |
1-year follow-up | 20.9 (4.3 − 62.1) | 10.0 (1.8 − 26.0) | 0.024 | 0.020 |
Postoperative day 1 urine output/hour, mL | 2.7 (2 – 3.7) | 2.33 (1.86 − 3.11) | 0.021 | 0.031 |
Postoperative day 2 urine output/hour, mL | 1.42 (1.13 – 1.72) | 1.48 (1.2 − 1.87) | 0.324 | 0.277 |
AKI, n (%) | 0.945 | 0.945 | ||
Stage 1 | 18 (8.5%) | 10 (9.1%) | ||
Stage 2 | 6 (2.8%) | 4 (3.6%) | ||
Stage 3 | 2 (0.9%) | 1 (0.9%) | ||
Postoperative kidney replacement therapy, n (%) | 2 (0.9%) | 0 (0%) | 0.550 | 0.550 |
Type of AKI | 0.110 | 0.110 | ||
Serum creatinine criteria | 19 (9.0%) | 15 (13.6%) | ||
Urine output criteria | 4 (1.9%) | 0 (0%) | ||
Both criteria | 3 (1.4%) | 0 (0%) | ||
AKI reversal state at discharge, n (%) d | 0.139 | 0.139 | ||
Reversal | 21/26 (80.8%) | 15/15 (100%) | ||
Non-reversal | 5/26 (19.2%) | 0 (0%) |